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Single nucleotide variants in IDH1, IDH2, TP53, H3F3A, 
and the TERT promoter region were identified using deep 
amplicon sequencing. Nanopore sequencing yielded ~0.1X 
genome coverage within 6 h and resulting CN and epige-
netic profiles correlated well with matched microarray data. 
Diagnostically relevant alterations, such as 1p/19q codele-
tion, and focal amplifications could be recapitulated. Using 
ad hoc random forests, we could perform supervised pan-
cancer classification to distinguish gliomas, medulloblasto-
mas, and brain metastases of different primary sites. Sin-
gle nucleotide variants in IDH1, IDH2, and H3F3A were 
identified using deep amplicon sequencing within minutes 
of sequencing. Detection of TP53 and TERT promoter 
mutations shows that sequencing of entire genes and GC-
rich regions is feasible. Nanopore sequencing allows same-
day detection of structural variants, point mutations, and 
methylation profiling using a single device with negligible 
capital cost. It outperforms hybridization-based and current 
sequencing technologies with respect to time to diagnosis 
and required laboratory equipment and expertise, aiming to 
Abstract Molecular classification of cancer has entered 
clinical routine to inform diagnosis, prognosis, and treat-
ment decisions. At the same time, new tumor entities have 
been identified that cannot be defined histologically. For 
central nervous system tumors, the current World Health 
Organization classification explicitly demands molecular 
testing, e.g., for 1p/19q-codeletion or IDH mutations, to 
make an integrated histomolecular diagnosis. However, a 
plethora of sophisticated technologies is currently needed 
to assess different genomic and epigenomic alterations and 
turnaround times are in the range of weeks, which makes 
standardized and widespread implementation difficult and 
hinders timely decision making. Here, we explored the 
potential of a pocket-size nanopore sequencing device for 
multimodal and rapid molecular diagnostics of cancer. 
Low-pass whole genome sequencing was used to simulta-
neously generate copy number (CN) and methylation pro-
files from native tumor DNA in the same sequencing run. 
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make precision medicine possible for every cancer patient, 
even in resource-restricted settings.
Keywords Nanopore sequencing · Brain tumor · Glioma · 
Whole genome sequencing · Epigenomics · Molecular 
neuropathology
Introduction
Histomolecular classification of brain tumors has entered 
clinical routine diagnostics as the current World Health 
Organization (WHO) classification explicitly demands his-
tological findings to be refined by molecular testing [20]. 
Thus, pathologists rely on timely and accurate molecular 
testing to make an integrated diagnosis using both in situ 
methods and genetic information. However, high turna-
round time of current implementations delays integrated 
diagnosis by weeks. In addition, targeted next-generation 
sequencing panels, microarray-based analysis of copy 
number (CN), and epigenetic alterations all provide high-
quality data and aid in the diagnosis and therapeutic man-
agement of patients (i.e., stratification or identification of 
actionable targets or inclusion in clinical trials), but their 
high capital cost, demanding workflows and need for 
highly skilled personnel hinder their widespread use. Here, 
we demonstrate that real-time molecular genomics using 
nanopore sequencing is both fast and reliable to aid diag-
nosing cancer by unsupervised classification of CN and 
methylation profiles.
Nanopore sequencing interprets changes in ionic cur-
rents observed when single DNA molecules pass through 
a nanometer-size protein pore. This has led to the develop-
ment of handheld size devices that allow sequencing out-
side of classical laboratory settings and even in the field 
[27]. While overall throughput currently lacks behind 
other deep sequencing technologies, nanopores allow read 
analysis in real-time and selective sequencing [19], both 
of which allow rapid generation of data. In addition, nano-
pores are able to discriminate not only the nucleotides of a 
strand of DNA but also single base modifications such as 
5-methylation of cytosine [29, 35]. This allows concurrent 
analysis of sequence identity and methylation using native 
DNA.
Materials and methods
Experimental design
We performed a retrospective observational study for 
molecular characterization of diagnostically relevant 
genetic alterations using nanopore sequencing. Patients 
were recruited at the Pitié-Salpêtrière university hospital 
and have given informed consent for research use of tumor 
material, including genotyping. All tumor samples have 
been molecularly characterized previously using short-read 
exome sequencing, Sanger sequencing, SNP array, and/or 
genome-wide methylation microarray [14, 30].
Nanopore whole genome sequencing
DNA quality of fresh-frozen tumor tissue was determined 
using NanoDrop (Thermo Fisher Scientific) and samples 
were quantified using a QuantiFluor dsDNA assay (Pro-
mega, Madison, WI, USA). For whole genome sequencing, 
libraries were prepared using Rapid 1D Sequencing Kit 
(SQK-RAD001, SQK-RAD002, or SQK-RBK001, Oxford 
Nanopore Technologies, UK) following the manufacturer’s 
instructions. Briefly, 200 ng of tumor DNA was fragmented 
using a transposase and subjected to adapter ligation. 
Sequencing was performed using R9 or R9.4 flow cells on 
a MinION Mk 1B device (Oxford Nanopore) with the Min-
KNOW software (versions 1.0.5–1.5.12), respectively. For 
samples run with R9.4 sequencing chemistry, basecalling 
was performed using Albacore 1.1.0 (Oxford Nanopore). 
For R9 chemistries, online EPI2ME basecalling (Metrichor 
Ltd, Oxford, UK) was performed.
Template reads were exported as FASTA using nanopol-
ish or poretools version 0.6 [18] and aligned to the hg19 
human reference genome using BWA MEM 0.7.12 with the 
“−x ont2d” option [17]. Due to compatibility issues of data 
generated with R9 chemistries, only samples with R9.4 
flow cells were used for copy number analysis and methyl-
ation-based classification.
Copy number analysis
For copy number analysis, the QDNAseq package version 
1.8.0 [33] and R/Bioconductor, version 3.3, were used. 
Reads with a minimum mapping quality of 20 were sorted 
into 1000 kbp bins. Bins with missing reference sequence 
were excluded from analysis. To account for region- and 
technology-specific artifacts, public nanopore WGS data 
for the NA12878 human reference genome were processed 
identically and subtracted from the normalized tumor 
sample bin counts. Circular binary segmentation was per-
formed as implemented in the DNAcopy package requiring 
an alpha value <0.05 to accept change points. Arm-level 
copy number calls were made by calculating the segment 
length weighted mean log ratio per chromosome arm.
Methylation analysis
To identify 5-methylation of cytosines, we used a recently 
published algorithm based on a hidden Markov model 
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which has been trained using in vitro methylated E. coli 
DNA [35]. Training models for R9 sequencing chemistries 
were kindly provided by Jared Simpson. We modified the 
original implementation of nanopolish 0.6.0 to allow meth-
ylation calling from different basecalling groups. For clas-
sification, the subset of CpG sites overlapping with sites 
covered by Illumina 450K BeadChip microarrays was used. 
Beta values in the training set were dichotomized using a 
cut-off value of 0.6.
Structural variant detection
For detection of structural variants in amplified regions, 
we aligned nanopore FASTQ files from sample 3427T to 
the human reference genome, build GRCh37, using LAST 
(version 744) with settings: −Q 0. The last-train function 
was used with 1000 nanopore reads (~10 million bases) as 
input to adapt the alignment scoring parameters (−p) for 
error-prone nanopore reads. LAST alignment files (MAF) 
were converted to BAM files using the maf-convert func-
tion. BAM files were used as input for NanoSV [36] (avail-
able at https://github.com/mroosmalen/nanosv) with default 
settings.
Amplicon sequencing
Amplicons were designed to cover one or multiple exons 
of canonical transcripts of IDH1, IDH2, TP53, H3F3A, 
and the TERT promoter region. Oligonucleotide prim-
ers (Thermo Fisher Scientific) were then designed using 
Primer3 with the following non-default parameters (Tmin 
59 °C, Topt 60 °C, Tmax 61 °C, and maximum mononu-
cleotide repeat length = 3) to yield product sizes of 489–
2902 bp (Table S1).
25 ng of genomic DNA was amplified using 0.02 U/
µl Q5 polymerase (New England Biolabs, Ipswich, MA, 
USA), 200 µM dNTPs, 500 nM forward and reverse prim-
ers, and Q5 reaction buffer with high GC enhancer in a total 
reaction volume of 20 µl. Thermal cycling was performed 
as follows: 98 °C initial denaturation for 2 min, followed 
by 30 cycles of denaturation at 98 °C for 10 s, annealing at 
65 °C for 20 s and extension at 72 °C for 90 s, as well as 
a final extension at 72 °C for 2 min. Amplicons were ana-
lyzed using a Caliper LabChip GX DNA 5K assay (Perkin 
Elmer, Waltham, MA, USA). PCR products were purified 
using NucleoFast 96 PCR plates (Macherey–Nagel, Düren, 
Germany).
For amplicon sequencing, Ligation Sequencing Kit 1D 
(SQK-LSK108, Oxford) was used following the manufac-
turer’s protocol. Briefly, 1 µg of pooled amplicon DNA 
was subjected to end repair and dA-tailing. 250 ng of end-
repaired DNA (equivalent to 0.2 pmol of 2 kbp fragments) 
was then used as input for adapter ligation. For real-time 
monitoring of sequencing depth, reads were streamed to the 
BWA aligner using npReader [6] with jHDF5 2.11.0 and 
coverage was calculated using BEDTools [28]. For variant 
calling, reads were realigned on the event level and vari-
ants called using VarScan 2.4.3 [15]. Variants were anno-
tated using SnpEff version 4.3i [9] and ExAC release 0.3.1 
germline variants [16] before filtering for coding or hotspot 
mutations with a minimum mutant allele frequency >0.2.
Microarray methylation profiling
Samples for Illumina Infinium BeadChip 450K profiling 
were prepared as described before [14]. Briefly, 500 ng 
of DNA was subjected to bisulfite conversion. Hybridiza-
tion and imaging were performed by IntegraGen (Evry, 
France). Raw IDAT files were preprocessed using the 
GenomeStudio software (Illumina, San Diego, CA, USA). 
Processed methylation data from previously characterized 
samples [14] were retrieved via ArrayExpress (accession 
E-MTAB-3903). Beta values were used for all the subse-
quent analysis steps.
Statistics
All data analysis was done using R/Bioconductor version 
3.3 [13]. Hierarchical clustering was used for arranging 
probes in the depicted classification training set. Random 
forest classification as implemented in the R/randomForest 
package, version 4.6–12, was run with default parameters. 
Sequence concordance was calculated using the Genome 
Analysis Toolkit’s Genotype Concordance tool, version 3.7 
[21].
Data and material availability
Raw sequencing data are available via the European 
Genome–phenome Archive (accession EGAS00001002213). 
Microarray-based methylome data are available at Array-
Express (E-MTAB-5797). TCGA data were retrieved from 
the UCSC Cancer Browser [11] or the TCGA FireBrowse 
website (http://www.firebrowse.org). Pipelines, scripts, and 
supplementary data to reproduce all results presented in 
this work are available at https://gitlab.com/pesk/glioma.
nano-seq.
Results
To meet the needs of the WHO 2016 classification of 
CNS tumors, we designed 1-day workflows for CN, 
methylation, and point mutation profiling using nanopore 
sequencing (Fig. 1a). We first subjected tumor DNA from 
molecularly well-characterized brain tumors [14, 30] to 
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low-pass whole genome sequencing (WGS) using a com-
mercially available, handheld size nanopore sequencing 
device. With the aim of widespread implementation in 
routine diagnostics in mind, we used a transposon-based 
library preparation kit, which reduces sample preparation 
time to less than hour. In a cohort of 28 patients (Table 1), 
low-pass WGS for 6 h performed yielded a mean mapped 
read depth from <0.01X to 0.24X (Table S1), depending 
on the sequencing chemistry and input DNA fragment 
size. Nanopores decipher DNA sequence of single mol-
ecules as they present to the pore, generating long reads 
of variable length, whose distribution is determined by 
DNA extraction and fragmentation method. We observed 
typical mean read lengths around 2 kb (Fig. 1b). As 
library preparation does not involve PCR amplification, 
no GC bias is introduced and the GC content distribution 
of the reads resembles closely that of the human refer-
ence genome (Fig. 1c).
Copy number profiling
We then used WGS data to generate CN profiles. Reads 
were counted in 1000 kb windows, normalized and sub-
jected to circular binary segmentation (Fig. 1c). No correc-
tion of GC bias or mappability is necessary for nanopore 
reads; however, the long reads cause alignment artifacts 
with current reference genomes in regions with repetitive 
sequence such as centromeres. Still, the resulting CN pro-
files closely resembled matched SNP array-based profiles 
(Fig. 1d). Importantly, codeletion of chromosome 1p/19q 
as a diagnostic criterion for oligodendrogliomas imple-
mented in the 2016 WHO classification of CNS tumors 
was detected in three out of four affected samples (Fig. S1). 
The remaining sample did not yield sufficient read depth 
(<0.01) due to low input DNA quality (Table S1). High-
level focal amplifications of EGFR, PDGFRA, and CDK4 
were detected in affected glioblastoma samples (Table 1). 
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Fig. 1  Copy number profiling using nanopore low-pass whole 
genome sequencing. a Same-day workflows to simultaneously char-
acterize copy number variation (CNV) and methylation profiles or 
single nucleotide variants, respectively. Tumor DNA is subjected 
to quality control (QC), and then, 250 ng input material is used for 
library preparation for either whole genome sequencing (WGS) or 
PCR-based deep amplicon sequencing. b Representative read length 
distribution of mapped reads. Note log scale on X axis. c Representa-
tive distribution of GC content of reads in comparison with the hg19 
human reference genome. A randomly drawn subsample of the entire 
reference genome split into 1000 bp fragments is shown. d Copy 
number profile showing  log2 transformed, normalized read counts per 
1000 kbp window (grey) with running mean (red) and segmentation 
results (blue). e Comparison of nanopore WGS with matched SNP 
arrays. Heatmaps indicate copy number calls (losses and deletions in 
blue, and gains and amplifications in red) across the genome
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Table 1  Clinical characteristics of patients in study
ID Age at diagnosis Sex WHO 2016 integrated 
diagnosis
Nanopore sequencing 
performed
Nanopore methylation-
based classification
Key alterations identified 
by nanopore sequencing
3523T 70 F Glioblastoma,  
IDH-wildtype
WGS, amplicon Not classifiable pTERT C228T
2197T 58 F Glioblastoma,  
IDH-wildtype
WGS, amplicon Glioma, IDH-wildtype TP53 p.S241F, pTERT 
C228T
3427T 72 F Glioblastoma,  
IDH-wildtype
WGS, amplicon Glioma, IDH-wildtype pTERT C228T, 
 CDKN2Aloss,  EGFRamp
2402T 58 M Anaplastic oligodendro-
glioma, IDH-mutant, 
and 1p/19q-codeleted
WGS, amplicon Not classifiable IDH1 p.R132H, 1p/19q 
codeletion, pTERT 
C228T
2965T 29 F Anaplastic oligodendro-
glioma, IDH-mutant 
and 1p/19q-codeleted
WGS, amplicon Glioma, IDH-mutant IDH1 p.R132H, 1p/19q 
codeletion, pTERT 
C228T
2483T 51 F Anaplastic astrocytoma, 
IDH-mutant
WGS, amplicon Glioma, IDH-mutant IDH1 p.R132C
TP53 p.R273C, p.R282Q
2922T 44 M Diffuse astrocytoma, 
IDH-mutant
WGS Glioma, IDH-mutant N/D
6228T 33 F Diffuse midline glioma, 
H3.3 K27M-mutant
WGS, amplicon Classifiable PDGFRAamp
5337T 21 M Glioma H3.3 G34R WGS, amplicon Glioma IDH-wildtype H3F3A G34R,  CDK4amp, 
 PDGFRAamp
8347T 28 M Desmoplastic/nodular 
medulloblastoma, 
SHH-activated and 
TP53 wild type
Amplicon N/D pTERT C228T
8372T 25 M Classic medulloblas-
toma, non-WNT/
non-SHH
WGS, amplicon Medulloblastoma, 
group 4
pTERT C228T
MB683 7 F Classic medulloblas-
toma, WNT-activated
WGS, amplicon Medulloblastoma, 
WNT-activated
chr6 loss
8137T 48 M Anaplastic oligodendro-
glioma, IDH-mutant 
and 1p/19q-codeleted
WGS, amplicon Glioma, IDH-mutant IDH2 p.R172 W, 1p/19q 
codeletion, pTERT 
C228T
8146T N/A F Anaplastic oligodendro-
glioma, IDH-mutant 
and 1p/19q-codeleted
WGS, amplicon Glioma, IDH-mutant pTERT C228T
7382T 76 F Glioblastoma,  
IDH-wildtype
WGS, amplicon Glioma, IDH-wildtype pTERT C228T, 
 PDGFRAamp
TP53 p.V197M
7455T 45 M Glioblastoma,  
IDH-wildtype
WGS, amplicon Glioma, IDH-wildtype pTERT C228T
8355T 56 M Glioblastoma,  
IDH-wildtype
WGS Not classifiable N/D
8356T 73 F Breast adenocarcinoma, 
GFAP+, S100+
WGS Breast cancer N/D
8357T 79 M Neuro-endrocrine (pros-
tate adeno) carcinoma, 
TTF1+
WGS Lung cancer N/D
8358T 63 F Lung adenocarcinoma WGS Lung cancer N/D
8359T 51 M Bladder urothelial 
carcinoma
WGS, amplicon Not classifiable TP53 p.R280 K
8360T 65 F Lung adenocarcinoma Amplicon N/D TP53 p.I195T
4596T FFPE 44 F Anaplastic oligodendro-
glioma, IDH-mutant 
and 1p/19q-codeleted
WGS, amplicon Not classifiable pTERT C228T
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In contrast, focal deletions, such as CDKN2A, were fre-
quently missed by segmentation. Beyond diagnostic needs, 
we could reconstruct the double minute nature of an EGFR 
amplification (case 3427T), identify the exact genomic 
breakpoint using algorithmic structural variant discovery 
[36], and confirm the latter by Sanger sequencing (Fig. S2).
Methylation profiling
A major advantage of nanopore sequencing is the ability 
to detect base modifications, especially 5-methylation of 
cytosines, in native DNA without need for bisulfite con-
version. Epigenomic changes are functionally important 
in cancer, but also aid in delineating cancer entities. For 
example, IDH mutations cause a global hypermethylation 
of CpG islands [25], a phenotype of utmost prognostic 
importance in neuro-oncology. We thus aimed to detect the 
G-CIMP phenotype from nanopore reads.
First, we compared methylation events in CpG sites 
identified by nanopore sequencing to matched methylome 
microarrays. Good correlation was observed between sin-
gle read methylation status of a given CpG site and its cor-
responding beta value in microarray data (Fig. 2a). Next, 
we applied random forest (RF) classification to predict IDH 
mutation.
RF classification is a commonly used machine-learning 
algorithm based on randomly generated (weak) decision 
trees [3]. Majority votes then integrate decisions from the 
entire forest to provide robust classification. The challenge 
with low-pass WGS data is that it is not known beforehand 
which CpG sites will be sequenced and the classifier can be 
built upon. Therefore, we generated random forests ad hoc. 
With increasing numbers of probed CpG sites, we expect 
the classifier’s error rate to decrease. To test the feasibility 
of this approach, we simulated multiple random forests for 
a given number of CpG sites using the low-grade glioma 
cohort [5] from The Cancer Genome Atlas (TCGA) and 
determined misclassification rate for this “random taiga” 
(Fig. 2b). The simulations show that the mean class error 
rate to predict IDH and 1p/19q status does not improve for 
more than approximately 500 CpG sites. This amount of 
data is reliably sampled within 6 h of nanopore sequenc-
ing. Thus, information with respect to a cancer’s entity is 
redundantly encoded in the methylome and this fact can be 
exploited for classification from sparse, randomly sampled 
CpG sites.
Using the same training set, we then predicted IDH sta-
tus in our samples from nanopore-based methylation calls. 
Due to the low read depth (usually N = 1), methylation 
calls from nanopore WGS were binary. To enable classi-
fication using microarray-based training data, beta values 
were dichotomized as described in previous applications of 
RF in methylation data [5, 7]. All samples were correctly 
classified (Fig. 2c).
Supervised pan‑cancer classification
Next, following the idea of a machine-learning-based 
molecular classification of tumors to fully recognize molec-
ular entities and rule out interobserver variability [32], we 
sought to investigate whether nanopore CN and methyla-
tion profiles can be used to classify tumor samples on a 
pan-cancer level. As a training set for all analyses, we used 
public microarray-based methylation data from primary 
brain tumors (adult and pediatric glioblastomas, lower 
grade gliomas, and medulloblastomas) and tumors that fre-
quently metastasize to the brain (melanoma, breast, lung, 
bladder, prostate, colon, and clear cell renal carcinoma) [1, 
Table 1  continued
ID Age at diagnosis Sex WHO 2016 integrated 
diagnosis
Nanopore sequencing 
performed
Nanopore methylation-
based classification
Key alterations identified 
by nanopore sequencing
5539T FFPE 28 M Anaplastic astrocytoma, 
IDH-mutant
Amplicon N/D pTERT  C228T¶
3718T 78 F Glioblastoma,  
IDH-wildtype
WGS N/D N/D
3719T 74 M Glioblastoma,  
IDH-wildtype
WGS N/D N/D
2211T 75 F Glioblastoma,  
IDH-wildtype
WGS N/D N/D
3724T 65 M Glioblastoma,  
IDH-wildtype
WGS N/D N/D
Age at initial diagnosis, integrated diagnosis and the type of nanopore sequencing performed are reported. Results of methylation-based random 
forest classification and key genetic alterations identified by WGS or amplicon sequencing are indicated. Samples were considered not classifi-
able when there was less than 5 percentage points difference of the majority vote to the next best vote
WGS whole genome sequencing, N/D not done
¶
  denotes false-positive variant
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2, 4, 5, 12, 23, 24, 37–40]. Where CN data were available, 
too, SNP array-based CN profiles were aggregated to chro-
mosome arm level and added to the training set (Fig. 3a). 
The resulting classifiers for any set of CpG sites in our 
cohort usually yielded an overall out-of-bag classification 
error rate ≪5%.
We first subjected seven glioma samples with CN and 
methylation profiles generated by nanopore sequencing to 
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Fig. 2  Methylome profiling by nanopore sequencing of native tumor 
DNA. a Comparison of methylation calls from nanopore sequenc-
ing with matched Illumina 450K microarray-based data. Beta value 
distributions for CpG sites that were identified as unmethylated (red) 
or methylated (blue), respectively, by nanopore WGS are shown. 
b “Random taiga” simulation of classification error as a function of 
the number of randomly sampled CpG sites. Each dot represents the 
class-specific error rate of an ad hoc generated random forest using a 
random subset of N CpG sites (indicated on X axis) from the TCGA 
lower grade glioma Illumina 450K cohort as training set. Lines indi-
cate the mean of five independent simulations. c Methylation profiles 
from nanopore sequencing discriminate IDH-mutant and wild-type 
tumors. Bar plots indicate vote distribution from ad hoc random for-
est classification. The TCGA low-grade glioma cohort was used as 
a training set. Illumina 450K-based beta values were dichotomized 
using >0.6 as threshold
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ad hoc RF classification. When we compared classifica-
tion using CN alone (Fig. 3b), methylation only (Fig. 3c) or 
both modalities together (Fig. 3d), using the joint approach 
improved overall accuracy: all (7/7) samples were correctly 
classified.
Then, we subjected two medulloblastoma (MB) cases 
to classification (here, only methylation training data were 
available). Both samples were identified as MB and also 
the genetic subtype according to the WHO classification 
was predicted correctly as WNT-activated (case MB683) or 
non-SSH-activated/non WNT-activated (i.e., group 4, case 
8372T) (Fig. 3e). Next, we attempted classification of brain 
metastasis and could predict the pulmonary origin in one 
case (Fig. 3f). We also selected a metastasis of a breast ade-
nocarcinoma in the posterior fossa for study which immu-
nohistochemically showed expression of GFAP and S100, 
so it was misleading for the diagnosis of carcinoma. Pan-
cancer classification based on nanopore WGS correctly 
identified this sample as breast cancer (Table 1, Fig. S1).
Several cases were not classifiable (requiring a > 5 per-
centage points’ difference of the majority vote to the next 
best vote) or misclassified (Table 1). These cases had often 
lower DNA quality with respect to fragment size (Table 
S1). One GBM sample that was not classifiable had low 
tumor purity when estimated from matched transcriptomic 
profiles using the ESTIMATE algorithm [41] (Fig. S3a). 
This also resulted in false-negative calling of copy num-
ber CN alterations using fixed thresholds, even though they 
were present at visual inspection (Fig. S3b).
Amplicon sequencing
Finally, we explored deep amplicon nanopore sequencing 
for identification of single nucleotide variants. We designed 
an amplicon panel covering hotspot exons in IDH1, IDH2, 
and H3F3A, all coding exons of TP53 and, addition-
ally, the TERT promoter (pTERT) region. Due to the long 
reads delivered by nanopore sequencing, this could be 
achieved with only nine PCR reactions (Table S2). Muta-
tions in these genes (with exception of pTERT) inform 
molecular diagnosis of glioma and medulloblastoma, and 
are demanded for diagnosis in the 2016 WHO classifica-
tion of CNS tumors [20]. Sufficient read depth is a criti-
cal parameter for variant calling with defined sensitivity 
and specificity. We thus implemented a real-time analysis 
pipeline that allowed monitoring of read depth and to stop 
sequencing when sufficient information to make a diagno-
sis has been collected (Fig. 4a). In samples run as single 
samples with real-time monitoring, a sequencing depth of 
1000X in all target regions could repeatedly be achieved 
within 2–20 min of sequencing. Mean overall coverage 
>1000X could be achieved in single runs, but was lower in 
runs using barcoding PCR for multiplexing (Fig. 4b).
In all samples, coding mutations were reliably detected 
as compared to routine diagnostics based on Sanger 
sequencing, immunohistochemistry or a next-generation 
sequencing (NGS) panel (Fig. 4c). Nanopore sequencing 
reads have historically shown high error rates, especially in 
homopolymer contexts. We, therefore, compared nanopore 
consensus sequences to matched short-read whole exome 
data in five cases. Overall concordance was 97.8–98.6% 
before functional filtering. Even though at low number 
(<5 per sample) after filtering for coding mutations, false-
positive variants were present. Most of these mutations 
occurred in multiple samples, indicating a context-specific 
error (Table S3). Improved base calling algorithms are thus 
needed to reduce the time to manually review mutations for 
false positives.
Technical aspects
Nanopore sequencing is highly scalable due to low capital 
cost of the device (use of multiple sequencers) and reuse of 
flow cells. To exclude carry-over and cross-contamination 
in sequential sequencing runs and for scalability, we evalu-
ated barcoding and multiplexing for both WGS and ampli-
con workflows (Table S1, Fig. 4b). For WGS, up to four 
samples were combined without major protocol changes 
and permitting convenient overnight runs (e.g., one sample 
for 6 h and two samples for 12 h). Barcoding of amplicon 
libraries and multiplexing 12 samples greatly reduces per-
assay price at the cost of additional PCR and quality control 
steps. Finally, we explored use of DNA derived from for-
malin-fixed paraffin-embedded tissue (FFPE). PCR ampli-
cons were generated from two FFPE samples with identical 
input amount and protocol. As expected from the usually 
highly fragmented DNA, PCR yields were lower, espe-
cially for large amplicons (>1 kbp). This could only partly 
be compensated by extending sequencing time. For nano-
pore WGS, transposase-based library preparation is not 
compatible with fragment size distribution of FFPE-derived 
Fig. 3  Pan-cancer classification using copy number and methylation 
profiles. a Training set composed of TCGA samples from nine can-
cer entities using arm-level averaged copy number (CN) information 
(CN loss blue, CN gain red) and dichotomized methylation data. For 
illustration purposes, only 200 random CpG sites were sampled, clus-
tered, and plotted. b–d Classification of samples subjected to WGS 
using R9.4 flow cells using ad hoc random forests (500 trees per sam-
ple). Bar plots show vote distributions based on copy number only 
(b), methylation (c), or both modalities (d). e, f Methylation-based 
pan-cancer classification of medulloblastoma (e) and a brain metas-
tasis of a lung adenocarcinoma (f). BRCA breast cancer, BLCA blad-
der urothelial carcinoma, COAD colon adenocarcinoma, KIRC kidney 
renal cell carcinoma, LUNG lung squamous cell and adenocarcinoma, 
SKCM skin cutaneous melanoma, PRAD prostate adenocarcinoma, 
MB medulloblastoma, K27 diffuse midline glioma H3 K27M mutant, 
G34 pediatric glioblastoma, H3 G34R mutant
◂
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DNA samples. We thus performed a different ligation pro-
tocol to test WGS in one FFPE sample. While read yield 
was acceptable (Table S1), the resulting copy number pro-
file was noisy and hard to interpret (Fig. S1). In summary, 
nanopore sequencing is compatible with FFPE samples, but 
clearly not recommended due to inferior performance.
Discussion
Histomolecular classification promises to significantly 
improve diagnosis, prognosis, and treatment decision 
making of cancer patients by aiding in clearly delineat-
ing distinct (molecular) entities and identifying targeta-
ble genomic alterations for personalized treatment. It is, 
therefore, crucial to ensure widespread implementation of 
appropriate technology in clinical routine for patient ben-
efit. We explored the potential of nanopore sequencing to 
comprehensively characterize genetic alterations.
CN alterations could be detected in brain tumor sam-
ples using ultra low-pass WGS. While overall resolution 
is lower than current SNP arrays or NGS approaches, arm-
level alterations and high-level focal alterations are reliably 
recapitulated. Most importantly, detection of 1p/19q-code-
letion fulfills diagnostic needs for the current WHO 2016 
classification of CNS tumors. While WGS using rapid, 
transposase-based library preparation works very well with 
high molecular weight DNA, some of the clinical routine 
fresh-frozen tumor DNA samples were highly fragmented 
and yielded insufficient results. Quality of input DNA thus 
seems to be pivotal. For use of FFPE material, changes to 
the protocol and further optimization are needed.
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Fig. 4  Real-time amplicon sequencing of single nucleotide vari-
ants. a Representative coverage plot of target regions in IDH1, 
IDH2, H3F3A, TP53, and TERT promoter region over time. The time 
needed to achieve 1000X depth in all amplicons is indicated. Note log 
scale on Y axis. b Mean read depth over all amplicons in samples pro-
cessed individually or as barcoded multiplex libraries. Of note, FFPE 
samples were sequenced as part of a multiplex library. c Comparison 
of selected variant calls from nanopore sequencing (filtered for cod-
ing or hotspot mutations with minimum allele frequency >0.2) with 
reference calls from Sanger or Illumina sequencing
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Methylation data can directly be obtained from the same 
WGS data set which makes time-consuming bisulfite con-
version and specialized methylation assays (sequencing or 
hybridization-based) expendable. Very recently, it has been 
shown in the context of meningioma that classification of 
tumors using methylome data alone is sufficient or superior 
to make a correct diagnosis [32]. With low genome cover-
age, we obtained sparse random sampling of CpG sites. We 
show that this information is sufficient to subtype gliomas 
into IDH-mutant vs. wild-type samples and that cancer 
entities from different tissue origins can be distinguished in 
a few hours. This may aid in the differential diagnosis of 
primary brain tumors vs. brain metastases and greatly facil-
itate staging and the search for unknown primary tumors 
[22]. However, as diagnosis is inferred from relatively 
sparse data, it precludes inter-patient comparison and reuse 
of data with currently obtainable coverage in the (relatively 
short) time frame of 6 h of sequencing.
Finally, we used PCR-based amplicon generation fol-
lowed by nanopore sequencing to identify point mutations. 
Using a small, but diagnostically relevant gene panel (cov-
ering target regions with a total of 12 kb), high read depth 
could be routinely obtained in less than 30 min of sequenc-
ing when using real-time depth monitoring. However, 
context-specific base calling errors introduce platform-spe-
cific errors and false variant calls that need to be carefully 
reviewed.
Comparison to existing technologies
Targeted next-generation sequencing panels tailored to 
detect mutations in brain tumors or, more generally, can-
cer-related genes have been employed routinely with a 
turnaround time of several days [8, 31]. Methylation-based 
classification of brain tumors by microarray allows differen-
tiation of a wealth of different entities within 2 weeks [12, 
32]. Intraoperative subtyping of gliomas is possible using 
allele specific PCR for key alterations (IDH1, pTERT) but 
remains restricted to hotspot point mutations [34]. Similarly, 
CN changes and mutations have been detected in cell-free 
DNA from CSF to allow less invasive diagnostics [10, 26]. 
A major drawback of all approaches is the high investment 
cost, need for laboratory space or expertise.
For nanopore sequencing, besides the portable 
sequencing device and a laptop computer, only a spec-
trometer for DNA quantification and a thermocycler for 
library preparation and amplicon generation by PCR are 
needed. This allows implementation of a complete molec-
ular pathology laboratory even in resource-restricted set-
tings or mobile environments. Per sample cost is ~$200 
for WGS and ~$120 for amplicon sequencing without 
multiplexing. However, being a technology still under 
development, frequent updates in chemistry and software 
currently challenge routine use and need to be addressed 
to allow standardized diagnostics across laboratories. In 
addition, hybridization microarrays and targeted short-
read sequencing both work relatively well with frag-
mented DNA from FFPE samples, while this currently 
poses a technical challenge for nanopore sequencing.
Our study has several limitations. First, as this is a 
proof-of-principle study, sample number is small and 
precludes accurate quantification of sensitivity or speci-
ficity to detect structural alterations and point mutations. 
Second, a prospective and multi-centric evaluation of 
the approach presented here is needed to rule out sample 
selection bias and demonstrate robustness across labo-
ratories. Third, we reused flow cells to reduce per-assay 
cost, but washing also decreased the number of active 
pores and thus performance in subsequent runs.
In conclusion, same-day diagnosis of CN alterations, 
epigenetic modifications, and single nucleotide vari-
ants using nanopore sequencing is feasible with minimal 
capital cost and without need for sophisticated labora-
tory equipment. For CNS tumors, molecular features 
demanded for diagnosis by current guidelines can be 
obtained, which, together with histological data and grad-
ing, enable accelerated integrated diagnosis and improve 
patient care.
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